Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin vs Methylprednisolone in Toxic Optic Neuropathy
NCT05748561Phase 3Unknown
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of erythropoietin in toxic optic neuropathy (TON), sponsored by Asociación para Evitar la Ceguera en México. Status: unknown.
02
Drugs
erythropoietin
03
Conditions
toxic optic neuropathy (TON)
Beyond the preview
Go deeper on NCT05748561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748561.